490 related articles for article (PubMed ID: 22968184)
1. Everolimus and erlotinib as second- or third-line therapy in patients with advanced non-small-cell lung cancer.
Papadimitrakopoulou VA; Soria JC; Jappe A; Jehl V; Klimovsky J; Johnson BE
J Thorac Oncol; 2012 Oct; 7(10):1594-601. PubMed ID: 22968184
[TBL] [Abstract][Full Text] [Related]
2. Erlotinib in advanced non-small cell lung cancer: efficacy and safety findings of the global phase IV Tarceva Lung Cancer Survival Treatment study.
Reck M; van Zandwijk N; Gridelli C; Baliko Z; Rischin D; Allan S; Krzakowski M; Heigener D
J Thorac Oncol; 2010 Oct; 5(10):1616-22. PubMed ID: 20736854
[TBL] [Abstract][Full Text] [Related]
3. Sunitinib plus erlotinib for the treatment of advanced/metastatic non-small-cell lung cancer: a lead-in study.
Blumenschein GR; Ciuleanu T; Robert F; Groen HJ; Usari T; Ruiz-Garcia A; Tye L; Chao RC; Juhasz E
J Thorac Oncol; 2012 Sep; 7(9):1406-16. PubMed ID: 22743295
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer.
Herbst RS; O'Neill VJ; Fehrenbacher L; Belani CP; Bonomi PD; Hart L; Melnyk O; Ramies D; Lin M; Sandler A
J Clin Oncol; 2007 Oct; 25(30):4743-50. PubMed ID: 17909199
[TBL] [Abstract][Full Text] [Related]
5. Erlotinib in combination with pemetrexed for patients with advanced non-small-cell lung cancer (NSCLC): a phase I dose-finding study.
Ranson M; Reck M; Anthoney A; Hanauske AR; Dean E; Melezinek I; Klingelschmitt G; Kletzl H; Blatter J; Twelves C
Ann Oncol; 2010 Nov; 21(11):2233-2239. PubMed ID: 20444843
[TBL] [Abstract][Full Text] [Related]
6. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study.
Seto T; Kato T; Nishio M; Goto K; Atagi S; Hosomi Y; Yamamoto N; Hida T; Maemondo M; Nakagawa K; Nagase S; Okamoto I; Yamanaka T; Tajima K; Harada R; Fukuoka M; Yamamoto N
Lancet Oncol; 2014 Oct; 15(11):1236-44. PubMed ID: 25175099
[TBL] [Abstract][Full Text] [Related]
7. Phase I Results from a Study of Crizotinib in Combination with Erlotinib in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer.
Ou SI; Govindan R; Eaton KD; Otterson GA; Gutierrez ME; Mita AC; Argiris A; Brega NM; Usari T; Tan W; Ho SN; Robert F
J Thorac Oncol; 2017 Jan; 12(1):145-151. PubMed ID: 27697581
[TBL] [Abstract][Full Text] [Related]
8. Phase 1 trial of everolimus and gefitinib in patients with advanced nonsmall-cell lung cancer.
Milton DT; Riely GJ; Azzoli CG; Gomez JE; Heelan RT; Kris MG; Krug LM; Pao W; Pizzo B; Rizvi NA; Miller VA
Cancer; 2007 Aug; 110(3):599-605. PubMed ID: 17577220
[TBL] [Abstract][Full Text] [Related]
9. Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer.
Herbst RS; Johnson DH; Mininberg E; Carbone DP; Henderson T; Kim ES; Blumenschein G; Lee JJ; Liu DD; Truong MT; Hong WK; Tran H; Tsao A; Xie D; Ramies DA; Mass R; Seshagiri S; Eberhard DA; Kelley SK; Sandler A
J Clin Oncol; 2005 Apr; 23(11):2544-55. PubMed ID: 15753462
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of everolimus-erlotinib in previously treated patients with advanced non-small-cell lung cancer.
Besse B; Leighl N; Bennouna J; Papadimitrakopoulou VA; Blais N; Traynor AM; Soria JC; Gogov S; Miller N; Jehl V; Johnson BE
Ann Oncol; 2014 Feb; 25(2):409-15. PubMed ID: 24368400
[TBL] [Abstract][Full Text] [Related]
11. A randomized phase 2 study of paclitaxel and carboplatin with or without conatumumab for first-line treatment of advanced non-small-cell lung cancer.
Paz-Ares L; Bálint B; de Boer RH; van Meerbeeck JP; Wierzbicki R; De Souza P; Galimi F; Haddad V; Sabin T; Hei YJ; Pan Y; Cottrell S; Hsu CP; RamLau R
J Thorac Oncol; 2013 Mar; 8(3):329-37. PubMed ID: 23370314
[TBL] [Abstract][Full Text] [Related]
12. Phase I and pharmacokinetic study of erlotinib administered in combination with amrubicin in patients with previously treated, advanced non-small cell lung cancer.
Otani S; Hamada A; Sasaki J; Wada M; Yamamoto M; Ryuge S; Takakura A; Fukui T; Yokoba M; Mitsufuji H; Toyooka I; Maki S; Kimura M; Hayashi N; Ishihara M; Kasajima M; Hiyoshi Y; Katono K; Asakuma M; Igawa S; Kubota M; Katagiri M; Saito H; Masuda N
Am J Clin Oncol; 2015 Aug; 38(4):405-10. PubMed ID: 26214085
[TBL] [Abstract][Full Text] [Related]
13. Rationale for a phase I trial of erlotinib and the mammalian target of rapamycin inhibitor everolimus (RAD001) for patients with relapsed non small cell lung cancer.
Johnson BE; Jackman D; Jänne PA
Clin Cancer Res; 2007 Aug; 13(15 Pt 2):s4628-31. PubMed ID: 17671154
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of erlotinib in 1242 East/South-East Asian patients with advanced non-small cell lung cancer.
Mok T; Wu YL; Au JS; Zhou C; Zhang L; Perng RP; Park K
J Thorac Oncol; 2010 Oct; 5(10):1609-15. PubMed ID: 20808255
[TBL] [Abstract][Full Text] [Related]
15. Phase II randomized trial of erlotinib or vinorelbine in chemonaive, advanced, non-small cell lung cancer patients aged 70 years or older.
Chen YM; Tsai CM; Fan WC; Shih JF; Liu SH; Wu CH; Chou TY; Lee YC; Perng RP; Whang-Peng J
J Thorac Oncol; 2012 Feb; 7(2):412-8. PubMed ID: 22157367
[TBL] [Abstract][Full Text] [Related]
16. Phase II trial of gefitinib and everolimus in advanced non-small cell lung cancer.
Price KA; Azzoli CG; Krug LM; Pietanza MC; Rizvi NA; Pao W; Kris MG; Riely GJ; Heelan RT; Arcila ME; Miller VA
J Thorac Oncol; 2010 Oct; 5(10):1623-9. PubMed ID: 20871262
[TBL] [Abstract][Full Text] [Related]
17. Randomized phase II multicenter trial of two schedules of lapatinib as first- or second-line monotherapy in patients with advanced or metastatic non-small cell lung cancer.
Ross HJ; Blumenschein GR; Aisner J; Damjanov N; Dowlati A; Garst J; Rigas JR; Smylie M; Hassani H; Allen KE; Leopold L; Zaks TZ; Shepherd FA
Clin Cancer Res; 2010 Mar; 16(6):1938-49. PubMed ID: 20215545
[TBL] [Abstract][Full Text] [Related]
18. Double-blind, placebo-controlled, randomized phase 2 study of the proapoptotic agent AT-101 plus docetaxel, in second-line non-small cell lung cancer.
Ready N; Karaseva NA; Orlov SV; Luft AV; Popovych O; Holmlund JT; Wood BA; Leopold L
J Thorac Oncol; 2011 Apr; 6(4):781-5. PubMed ID: 21289522
[TBL] [Abstract][Full Text] [Related]
19. Phase I study of the HER3-targeted antibody patritumab (U3-1287) combined with erlotinib in Japanese patients with non-small cell lung cancer.
Nishio M; Horiike A; Murakami H; Yamamoto N; Kaneda H; Nakagawa K; Horinouchi H; Nagashima M; Sekiguchi M; Tamura T
Lung Cancer; 2015 Jun; 88(3):275-81. PubMed ID: 25891541
[TBL] [Abstract][Full Text] [Related]
20. Combined Pan-HER and ALK/ROS1/MET Inhibition with Dacomitinib and Crizotinib in Advanced Non-Small Cell Lung Cancer: Results of a Phase I Study.
Jänne PA; Shaw AT; Camidge DR; Giaccone G; Shreeve SM; Tang Y; Goldberg Z; Martini JF; Xu H; James LP; Solomon BJ
J Thorac Oncol; 2016 May; 11(5):737-747. PubMed ID: 26899759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
